AbbVie Inc (ABBV)

ABBV (NYSE:Drugs) EQUITY
$62.71
pos +0.00
+0.00%
Today's Range: 61.90 - 63.20 | ABBV Avg Daily Volume: 7,664,000
Last Update: 05/27/16 - 4:02 PM EDT
Volume: 0
YTD Performance: 5.86%
Open: $0.00
Previous Close: $61.90
52 Week Range: $45.45 - $71.60
Oustanding Shares: 1,617,358,607
Market Cap: 100,114,497,773
6-Month Chart
TheStreet Ratings Grade for ABBV
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 8 8 9 9
Moderate Buy 1 1 1 1
Hold 3 3 3 2
Moderate Sell 0 0 0 0
Strong Sell 1 1 0 0
Mean Rec. 1.81 1.81 1.50 1.38
Latest Dividend: 0.57
Latest Dividend Yield: 3.76%
Dividend Ex-Date: 04/13/16
Price Earnings Ratio: 18.23
Price Earnings Comparisons:
ABBV Sector Avg. S&P 500
18.23 18.50 12.90
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
11.98% -6.93% 38.01%
GROWTH 12 Mo 3 Yr CAGR
Revenue 14.50 0.20 0.07
Net Income 190.00 0.00 -0.01
EPS 185.20 -0.10 -0.02
Earnings for ABBV:
EBITDA 8.37B
Revenue 22.86B
Average Earnings Estimates
Qtr (06/16) Qtr (09/16) FY (12/16) FY (12/17)
Average Estimate $1.20 $1.18 $4.77 $5.67
Number of Analysts 8 6 10 9
High Estimate $1.21 $1.24 $4.85 $5.92
Low Estimate $1.19 $1.14 $4.69 $5.35
Prior Year $1.08 $1.13 $4.29 $4.77
Growth Rate (Year over Year) 11.11% 4.28% 11.17% 18.82%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
The market is having a quiet day in front of the long holiday weekend. However, biotech is concluding another strong week, which makes two in a row. I'm noticing some small biotechs on the move today.
Keep cash on hand and be ready for oportunities as they arise.
AbbVie and Gilead Sciences are worth accumulating in a long and deep bear market for biotech.
We offer 10 names each in the Opportunistic Value portfolio and the Income-Oriented portfolio.
Home Depot shares were falling despite a strong first-quarter showing. 
It is hard to see much growth in the market overall, until earnings growth returns.
And it's hard to get excited about the second quarter, too.
After an asset price drop, large pharmaceutical companies are looking for strategic purchases.
Larry Robbins, Carson Block and John Khoury hold court at the 2106 Sohn Conference.
The interest areas of these investors span health care, hotels and international intrigue. Real Money takes a quick look at what they may discuss Wednesday.

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.